Koru announces pact for next-gen subcutaneous immunoglobulin infusion system
Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...
drugdeliverybusiness1d
Koru Medical inks deal to develop next-gen subcutaneous infusion system
Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.
MedPage Today4d
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
San Francisco Examiner2d
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The American Journal of Managed Care4d
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
Business Wire9d
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...
Healio8d
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.